NAD+ · Research brief

Best Peptides for Perimenopause — Research Guide

Real Peptides Research TeamEditorial

Updated May 1, 20268 min read

56 WORDS

Short answer

Most published lists of the best peptides for perimenopause include at least two compounds that are not peptides. 5-Amino-1MQ is a small-molecule enzyme inhibitor. NAD+ is a dinucleotide coenzyme. Neither is a chain of amino acids, and that distinction changes how the material is synthesised, how purity is assayed, and how a vial behaves in storage.

Key takeaways

No peptide replaces estradiol or progesterone, and any framing that suggests otherwise misrepresents the mechanism entirely.
Growth-hormone secretagogues dominate this research area because somatopause and the perimenopausal transition overlap in timing, not because they act on ovarian hormones.
5-Amino-1MQ is a small-molecule NNMT inhibitor rather than a peptide, which changes both its identity verification method and its storage profile.
MOTS-c is encoded inside the mitochondrial 12S rRNA gene and is studied for AMPK activation, with a literature base that remains largely preclinical.
GHK-Cu has the longest-running tissue-level evidence base of the compounds discussed here, concentrated in dermal fibroblast research.
Every compound named in this brief is research use only and is not an approved drug product.

Our team supplies research-grade material to laboratories working on endocrine-transition models, and the same request arrives in different wording every week. The useful version of the question is narrower than the search phrase: which compounds have published literature touching the endpoints perimenopause research actually measures?

What are the best peptides for perimenopause research?

Research interest clusters into four groups: growth-hormone-axis secretagogues (CJC-1295 no DAC, Ipamorelin, Tesamorelin), metabolic and mitochondrial compounds (MOTS-c, 5-Amino-1MQ), connective-tissue and dermal peptides (GHK-Cu, BPC-157, TB-500), and neuro-inflammatory compounds (Selank, KPV). Every one of these is a research-use-only material, not a therapy.

Here is the misconception worth clearing first. No peptide in any catalog is hormone replacement, and none of the compounds discussed as the best peptides for perimenopause restores circulating estradiol or progesterone. They act on adjacent signalling systems that shift during the same window of life, which is precisely why the literature on them is interesting and also why it is easy to overstate. This brief covers how to match compound class to measured endpoint, the NAD+ and AMPK mechanisms most summaries skip, and what to verify on a certificate of analysis before procurement.

Matching compounds to the endpoints the research actually measures

Perimenopause research does not measure perimenopause. It measures endpoints: visceral adipose tissue, bone turnover markers, fasting insulin and HOMA-IR, dermal collagen density, sleep architecture, and inflammatory markers such as hs-CRP and IL-6. Any sensible shortlist of the best peptides for perimenopause is built backwards from whichever of those a study is designed to detect.

The overlap researchers keep returning to is somatopause, the age-related decline in growth hormone pulse amplitude and downstream IGF-1, which runs on a parallel timeline to the fluctuating estradiol and rising FSH that define the perimenopausal transition. That overlap is why growth-hormone secretagogues dominate the conversation.

CJC-1295 No DAC is a modified GRF 1-29 analog that binds the GHRH receptor on somatotrophs; without the drug affinity complex it has a short circulating life, which is why it appears in study designs interested in preserving pulsatile release rather than flattening it. Ipamorelin is a pentapeptide agonist at GHS-R1a, the ghrelin receptor, and the literature describes it as more selective than earlier growth-hormone-releasing peptides with respect to cortisol and prolactin. Tesamorelin is a stabilised GHRH analog studied in clinical trials of HIV-associated visceral adiposity, where reductions in visceral adipose tissue were reported. AOD-9604 is the hGH 176-191 fragment, investigated for lipolytic signalling decoupled from the IGF-1 response.

All compounds referenced here are supplied for laboratory research use only and are not drugs, supplements, or materials for human or veterinary consumption.

The metabolic mechanism most summaries skip: NAD+ salvage and AMPK

The metabolic arm of the best peptides for perimenopause discussion runs through two mechanisms that almost every consumer-facing article compresses into the word metabolism. Both are worth stating properly.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene, which makes it one of the few peptides in any catalog whose open reading frame sits inside the mitochondrial genome rather than the nucleus. Studies report AMPK activation, the cellular energy sensor that shifts substrate handling from storage toward oxidation, alongside changes in glucose disposal in rodent models. The literature also describes declining circulating MOTS-c with age, which is the observation driving most of the current research interest.

5-Amino-1MQ works through a completely different route. It inhibits NNMT, nicotinamide N-methyltransferase, an enzyme that methylates nicotinamide and in doing so consumes S-adenosylmethionine while diverting nicotinamide away from the NAD+ salvage pathway. Preclinical adipocyte work reports that inhibiting NNMT raises intracellular NAD+ and SAM. That mechanism also explains why it sits beside compounds like NAD+ liquid spray in research procurement lists.

Here is the practical consequence most guides miss entirely. Because 5-Amino-1MQ is a small molecule and MOTS-c is a peptide, they are not verified the same way. A peptide identity check leans on mass spectrometry against a calculated molecular weight; a small molecule is confirmed against its CAS number and structure. Buying both from one supplier and accepting one style of certificate for both is a documentation gap, not a shortcut.

Connective tissue, dermal, and neuro-inflammatory research lines

The third cluster covers the endpoints researchers reach for when the question is tissue quality rather than body composition. Dermal collagen, tendon remodelling, mucosal integrity, and inflammatory signalling all shift during the perimenopausal window, and the peptide literature here is older and more granular than the metabolic literature.

GHK-Cu is the copper-binding tripeptide glycyl-L-histidyl-L-lysine, studied extensively in dermal fibroblast models where research reports effects on collagen, decorin and matrix remodelling gene expression. The literature also describes a decline in plasma GHK with age. AHK-Cu is its alanyl-histidyl-lysine relative, studied mainly in dermal papilla and follicle research. BPC-157 is a pentadecapeptide derived from a gastric juice protein, investigated in rodent tendon and gastrointestinal models with angiogenic signalling through the VEGFR2 pathway frequently cited. TB-500 is the synthetic actin-sequestering fragment related to Thymosin Beta-4, used in cell-migration research.

On the inflammatory and neuro side, KPV is the C-terminal tripeptide of alpha-MSH studied for NF-kB modulation, and Selank is a synthetic heptapeptide analog of tuftsin with a Russian literature base examining anxiolytic and BDNF-related endpoints. Glutathione belongs here too, and it genuinely is a peptide: a tripeptide of glutamate, cysteine and glycine that oxidises readily, which is why redox-sensitive handling matters more with it than with almost anything else on this list.

Best Peptides for Perimenopause: Research Compound Comparison

The table sorts the commonly requested compounds by molecular class, the endpoint cluster their literature addresses, and how mature that evidence base currently is. Evidence maturity is the column most procurement decisions ignore and most study designs depend on.

Compound	Molecular class	Endpoint cluster studied	Evidence maturity	Bottom line for research use
CJC-1295 No DAC + Ipamorelin	GHRH analog + GHS-R1a pentapeptide agonist	GH pulse amplitude, IGF-1, body composition	Mechanistic and early human pharmacology; commonly paired in study designs	The most studied secretagogue pairing; suitable where pulsatile release is the variable of interest
Tesamorelin	Stabilised GHRH analog	Visceral adipose tissue, lipid handling	Strongest human trial base of the secretagogue group, in a non-menopausal population	Choose when the protocol needs a compound with published randomised human data rather than rodent work
MOTS-c	Mitochondrial-derived 16-aa peptide	AMPK activation, glucose disposal, exercise physiology	Largely preclinical, rapidly expanding	High mechanistic interest, thin human data; best framed as exploratory
5-Amino-1MQ	Small-molecule NNMT inhibitor, not a peptide	NAD+ salvage, adipocyte metabolism	Preclinical, primarily cell and rodent models	Verify by CAS number and structure, not by peptide mass spec
GHK-Cu / AHK-Cu	Copper-binding tripeptides	Dermal collagen, matrix remodelling, follicle biology	Decades of in vitro dermal literature	The deepest tissue-level evidence base of any compound listed here
BPC-157 / TB-500	Pentadecapeptide / actin-sequestering fragment	Tendon, mucosal and cell-migration models	Extensive rodent literature, no large human trials	Well characterised in animal models only; state that limitation in any write-up
Selank / KPV	Tuftsin heptapeptide analog / alpha-MSH tripeptide	BDNF and GABAergic signalling, NF-kB inflammation	Regional clinical literature and preclinical immunology	Useful where the endpoint is behavioural or inflammatory rather than metabolic

What If: Procurement and Handling Scenarios

What if a protocol requires published human trial data rather than rodent models?

Narrow the shortlist to Tesamorelin and, with caveats, the GHRH and GHS-R1a secretagogues that have published human pharmacology. Most of the compounds in this category rest on rodent or in vitro work, and BPC-157 in particular has no large human trial base despite the volume of animal literature. Stating that limitation explicitly in a methods section is better science than implying parity across compounds with very different evidence maturity.

What if lyophilised vials arrive warmer than expected after shipping?

Document the excursion, photograph the packaging and the vial, and contact the supplier before the material enters a study. Lyophilised peptides are considerably more tolerant of short ambient exposure than reconstituted solutions, but tolerance is not the same as verified integrity, and appearance tells you almost nothing about whether the sequence survived intact. Any material used after an undocumented excursion contaminates the reproducibility of everything downstream of it.

What if the certificate of analysis lists a purity percentage but nothing else?

Treat it as incomplete. A usable certificate pairs an HPLC purity figure with a mass spectrometry result confirming molecular weight against the calculated value for that exact sequence, plus the batch identifier and analysis date. Purity alone tells you how much of the vial is one substance. It does not tell you whether that substance is the compound you ordered.

What if two suppliers quote the same compound at very different prices?

Compare the analytical documentation before comparing the numbers. Small-batch synthesis with per-batch third-party testing carries real cost, and the gap between suppliers usually sits in whether every batch is tested or whether one historical certificate is reused across many lots. Our team has reviewed enough incoming documentation to say the pattern is consistent: the cheapest quote is almost always the one where batch-level traceability quietly disappears.

The Unglamorous Truth About Peptide Research in This Category

Let's be direct about this. The list of best peptides for perimenopause circulating online is not a list built from menopause research, because almost none of these compounds have been studied in perimenopausal populations at all. What exists is a set of mechanisms that plausibly intersect with endpoints that change during the transition. That is a legitimate starting point for a study design and a poor basis for a marketing claim. Anyone presenting these compounds as a solution to a life stage is skipping the part where the research still has to be done.

Researchers comparing suppliers can review batch documentation on the certificates of analysis page, browse the full catalog through the research peptide shop, and check handling and identity-verification questions in the peptide FAQ.

The search for the best peptides for perimenopause tends to assume there is a right answer waiting to be found, when the compound list is always downstream of the question being asked. A study measuring dermal collagen density and a study measuring visceral adipose tissue will produce two shortlists with no overlap, and both will be correct. That is the unromantic reality of a research area this young: the interesting work right now is not in ranking the compounds, it is in designing the endpoint precisely enough that a ranking would mean something.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

Research interest concentrates on four groups: growth-hormone-axis secretagogues such as CJC-1295 No DAC, Ipamorelin and Tesamorelin; metabolic compounds including MOTS-c and 5-Amino-1MQ; connective-tissue and dermal peptides such as GHK-Cu, BPC-157 and TB-500; and neuro-inflammatory compounds including Selank and KPV. Which group is appropriate depends entirely on the endpoint being measured. All are research use only and none is an approved drug product.

No. None of the compounds discussed in this category restores circulating estradiol or progesterone, and no peptide in any research catalog functions as hormone replacement. They act on separate signalling systems, including the growth hormone axis, AMPK-mediated metabolic pathways, and matrix remodelling in dermal tissue. Framing them as hormone therapy misrepresents both the mechanism and the regulatory status.

It appears on those lists because of its metabolic mechanism, not its molecular class. 5-Amino-1MQ is a small-molecule inhibitor of NNMT, the enzyme that methylates nicotinamide and diverts it away from the NAD+ salvage pathway. The classification matters practically: it should be verified against its CAS number and chemical structure rather than by peptide mass spectrometry.

A complete certificate pairs an HPLC purity result with mass spectrometry confirming molecular weight against the calculated value for the specific sequence, plus a batch identifier and the date of analysis. Purity alone confirms homogeneity, not identity. Real Peptides publishes batch documentation so buyers can match a vial to the analysis that covers it.

Research-use-only compounds are supplied for laboratory investigation and are not evaluated or approved as drug products for human or veterinary use. Prescription medications carry approved labelling, defined indications, and regulated manufacturing for finished dosage forms. The molecule may be chemically identical in some cases, but the regulatory pathway, permitted use, and documentation requirements are entirely different.

Tesamorelin has the strongest human trial base of the compounds commonly named, from clinical research in HIV-associated visceral adiposity rather than menopause populations. The GHRH and GHS-R1a secretagogues have published human pharmacology data. MOTS-c, 5-Amino-1MQ, BPC-157 and TB-500 rest largely on preclinical and rodent literature, which should be stated explicitly in any research write-up.

Pricing varies widely by compound, vial size, and how much analytical testing a supplier performs per batch. Complex or longer sequences cost substantially more to synthesise than short tripeptides such as GHK-Cu or KPV. The most common driver of a low quote is reduced batch-level testing, so compare the analytical documentation before comparing prices.

Lyophilised material is generally stored frozen and protected from light and moisture, with cold-chain conditions maintained in transit. Once a peptide is in solution it becomes considerably less stable than the dry powder, and redox-sensitive compounds such as glutathione degrade faster still. Suppliers should provide compound-specific storage guidance on the product documentation rather than a single blanket instruction.

Both are copper-binding tripeptides, but their studied applications diverge. GHK-Cu, glycyl-L-histidyl-L-lysine, has the deeper literature base in dermal fibroblast research covering collagen and matrix remodelling gene expression. AHK-Cu, alanyl-histidyl-lysine, has been investigated more narrowly in dermal papilla and hair follicle models.

Because somatopause, the age-related decline in growth hormone pulse amplitude and downstream IGF-1, runs on a similar timeline to the perimenopausal transition. Secretagogues such as CJC-1295 No DAC and Ipamorelin act on the GHRH receptor and GHS-R1a respectively, which is a separate axis from ovarian hormone production. The overlap is chronological, not causal, and the distinction matters when interpreting results.

Research-use-only suppliers sell material for laboratory investigation and cannot lawfully market it for human or veterinary consumption. Real Peptides supplies catalog compounds to researchers and laboratories with accompanying certificates of analysis, and does not provide dosing, administration, or protocol guidance. Anything presented as a human treatment from a research supplier is a compliance red flag.

Batch-level traceability is the clearest differentiator. Reliable suppliers run small-batch synthesis with per-batch third-party analysis and publish the resulting certificates, so a specific vial can be matched to a specific test. Less rigorous suppliers reuse a single historical certificate across many lots, which means the document on file may describe material that has no relationship to what arrived.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA